The Infectious Disease Research Institute (IDRI) has been awarded a two-year $300,000 grant from The Paul G. Allen Family Foundation to support IDRI's launch of a phase I clinical trial of its new tuberculosis vaccine known as ID93/GLA-SE.  The phase I trial will evaluate the safety and immunogenicity of ID93/GLA-SE in a group of healthy volunteers, and is expected to begin in early 2012.

"We are thrilled to be supporting IDRI, a Seattle based not-profit organization focused on addressing infectious diseases, in its effort to develop a vaccine to fight tuberculosis," commented Susan M. Coliton, vice president of  The Paul G. Allen Family Foundation. "This new vaccine could be the solution for the world-wide TB pandemic affecting millions of people."